Professor Rob Coleman MBBS, MD, FRCP, FRCPE

Emeritus Professor of Medical Oncology, University of Sheffield

Rob Coleman new

Department of Oncology & Metabolism
Cancer Clinical Trials Centre
Academic Unit of Clinical Oncology
Weston Park Hospital
S10 2SJ

Office: Broomcross Building, Floor 2

Tel: +44 (0)114 226 5213
Fax: +44 (0)114 226 5364



Professor Robert (Rob) Coleman is Emeritus Professor of Medical Oncology at Weston Park Hospital and the University of Sheffield. He graduated in medicine from Kings College Hospital Medical School in 1978 and trained in London and Edinburgh before moving to Sheffield in 1991 where he was instrumental in developing clinical cancer research in the city and establishing an internationally respected bone oncology research team in Sheffield. Rob has held many leadership roles within the university and the National Institute for Health Research (NIHR) Cancer Research Network.

Recently retired from the university, Professor Coleman remains research active and has written more than 420 scientific articles and 60 book chapters and still leads a number of national and international clinical trials. He is a past-president of the Cancer and Bone Society, the founding editor of “Journal of Bone Oncology” and a trustee for Breast Cancer Now, the largest breast cancer research charity in the UK. He is also a Trustee at St Luke’s Hospice in Sheffield and for Weston Park Cancer Charity.

Since 2014 he has been a part-time Medical Director for the global independent medical education provider, prIME Oncology™ developing and delivering both live and on-line educational programmes for oncologists and other providers of cancer care.

Key Publications

  1. Brown J, Rathbone E, Hinsley S, Gregory W, Gossiel F, Marshall H, Burkinshaw R, Shulver H, Thandar H, Bertelli G, Keane M, Bowman A, Hanby A, Bell R, Cameron D, Coleman R. Associations Between Serum Bone Biomarkers in Early Breast Cancer and Development of Bone Metastasis: Results From the AZURE (BIG01/04) Trial. JNCI J Natl Cancer Inst (2018) 110(8): djx280
  2. Coleman R, Hall A, Albanell J, Hanby A, Bell R, Cameron D, Dodwell D, Marshall H, Jean-Mairet J, Tercero J-C, Rojo F, Gregory W, Gomis R. Effect of MAF amplification on treatment outcomes with adjuvant zoledronic acid in early breast cancer: a secondary analysis of the international, open-label, randomised, controlled, phase 3 AZURE (BIG 01/04) trial. Lancet Oncol 2017 Nov;18(11):1543-1552.
  3. Cameron D, Morden JP, Canney P, Velikova G, Coleman R, Bartlett J, Agrawal R, Banerji J, Bertelli G, Bloomfield D, Brunt AM, Earl H, Ellis P, Gaunt C, Gillman A, Hearfield N, Laing R, Murray N, Couper N, Stein RC, Verrill M, Wardley A, Barrett-Lee P, Bliss JM; TACT2 Investigators. Accelerated versus standard epirubicin followed by cyclophosphamide, methotrexate, and fluorouracil or capecitabine as adjuvant therapy for breast cancer in the randomised UK TACT2 trial (CRUK/05/19): a multicentre, phase 3, open-label, randomised, controlled trial. Lancet Oncol. 2017 Jul;18(7):929-945.
  4. Earl HM, Hiller L, Howard HC, Dunn JA, Young J, Bowden SJ, McDermaid M, Waterhouse AK, Wilson G, Agrawal R, O'Reilly S, Bowman A, Ritchie DM, Goodman A, Hickish T, McAdam K, Cameron D, Dodwell D, Rea DW, Caldas C, Provenzano E, Abraham JE, Canney P, Crown JP, Kennedy MJ, Coleman R, Leonard RC, Carmichael JA, Wardley AM, Poole CJ; tAnGo trial collaborators. Addition of gemcitabine to paclitaxel, epirubicin, and cyclophosphamide adjuvant 3jmchemotherapy for women with early-stage breast cancer (tAnGo): final 10-year follow-up of an open-label, randomised, phase 3 trial. Lancet Oncol. 2017 Jun;18(6):755-769
  5. Early Breast Cancer Trialists’ Collaborative Group (EBCTCG)* (Coleman R, Powles T, Paterson A, Gnant M, Anderson S, Diel I, Gralow J, von Minckwitz G, Moebus V, Bergh J, Pritchard K, Bliss J, Cameron D, Evans V, Hongchao Pan, Peto R, Bradley R, Gray R. Adjuvant bisphosphonate treatment in early breast cancer: meta-analyses of individual patient data from randomized trials. Lancet 2015, Oct 3;386(10001):1353-61.